Drug Research
APP Pharmaceuticals receives marketing approval for Methotrexate Injection
APP Pharmaceuticals, a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals, has received FDA approval to market preservative-free Methotrexate Injection, USP. APP worked with the FDA to expedite approval of the oncology drug due to...
Drug Research
Ranbaxy launches cholesterol reducing drug in Australia
Ranbaxy Australia, a subsidiary of Ranbaxy Laboratories, has introduced Atorvastatin 10mg, 20mg, 40mg and 80mg tablets after receiving approval from Therapeutic Goods Administration (TGA) in Australia. The product is launched under the brand name...
Drug Research
La Jolla buys GCS-100 rights from Solana
La Jolla Pharmaceutical Company has acquired global development and commercialization rights to GCS-100 from Solana Therapeutics. GCS-100 is an inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure. Galectin-3 plays...
Drug Research
Novartis receives Morrison & Foerster advice on Camurus deal
The global law firm, Morrison & Foerster has advised Novartis to sign an exclusive collaboration, option and license agreement with Camurus, a Swedish research-based pharmaceutical company. As per the collaboration, Camurus has granted Novartis...
Drug Research
Mymetics regains intra-nasal influenza vaccine from Solvay
Mymetics, a developer of next-generation preventative vaccines, has regained its intra-nasal influenza vaccine from Solvay.Mymetics has provided license of its intra-nasal flu vaccine, under which Solvay has developed the vaccine until 2008 and also completed phase I trial. ...
Drug Research
The Medicines Company introduces new Cleviprex formulation
The Medicines Company has launched a new twelve hour formulation for the FDA approved Cleviprex Injectable Emulsion.Cleviprex is an intravenous dihydropyridine calcium channel blocker, which helps in reduction of blood pressure when oral therapy is not feasible. ...
Drug Research
Theraclone doses first patient in Phase 1 TCN-032 drug trial
Theraclone Sciences has dosed first patient in a randomized, double-blind, dose-escalation Phase 1 trial investigating TCN-032 as a treatment for influenza A virus. TCN-032 was discovered utilizing Theraclone's I-STAR platform.The trial aims to investigate...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read